Chong Kun Dang Pharmaceutical has been granted a patent for novel compounds with HDAC6 inhibitory activity, effective in treating various diseases. The patent covers a 1,3,4-oxadiazole derivative compound and its isomers or salts. GlobalData’s report on Chong Kun Dang Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Chong Kun Dang Pharmaceutical's grant share as of April 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11958844B2) discloses a novel 1,3,4-oxadiazole derivative compound represented by a specific chemical formula, its optical isomer, or a pharmaceutically acceptable salt. The compound is characterized by the presence of various substituents and functional groups, making it suitable for pharmaceutical applications. The patent claims cover different variations of the compound, including specific configurations and substitutions, enhancing its potential utility in the field of medicine.
Furthermore, the patent describes the use of the 1,3,4-oxadiazole derivative compound as an active ingredient in pharmaceutical compositions aimed at preventing or treating diseases related to histone deacetylase 6 activity. These diseases encompass a wide range of conditions, including infectious diseases, neoplasms, neurological disorders, and metabolic diseases, among others. The patent also outlines a method for administering the compound effectively to treat or prevent histone deacetylase 6 activity-related diseases, highlighting its therapeutic potential in addressing various medical conditions.
To know more about GlobalData’s detailed insights on Chong Kun Dang Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
